- Enables development of first-in-class molecular radiotherapy based on PARP inhibitor - Offers significant potential for diagnosing and treating a broad range of cancers LONDON, Sept. 5, 2019 /PR...
Original Article: Theragnostics Signs Agreement with AstraZeneca